



(51) International Patent Classification:

A61K 35/12 (2015.01) A61P 35/00 (2006.01)
A61N 2/04 (2006.01) A61K 31/22 (2006.01)

(21) International Application Number:

PCT/SG2021/050613

(22) International Filing Date:

12 October 2021 (12.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202010091U 12 October 2020 (12.10.2020) SG

(71) Applicants: NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). ETH ZURICH [CH/CH]; Raemistrasse 101, 8092 Zurich (CH).

(72) Inventors: FRANCO-OBREGON, Alfredo; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Surgery, 21 Lower Kent Ridge Road, Singapore 119077 (SG). TAI, Yee Kit; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Surgery, 21 Lower Kent Ridge Road, Singapore 119077 (SG). KURTH, Felix; c/o ETH Zurich, Brunnenstrasse 30, 8049 Zurich (CH). DITTRICH, Petra Stephanie; c/o ETH Zurich, BSD H 368, Mattenstrasse 26, 4058 Basel (CH).

(74) Agent: DAVIES COLLISON CAVE ASIA PTE. LTD.; 10 Collyer Quay #07-01, Ocean Financial Centre, Singapore 049315 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: METHODS OF PREPARING CELL-DERIVED VESICLES




Figure 1

(57) Abstract: The invention relates generally to cell-derived vesicles (CDVs), such as CDVs from myoblast, wherein the parent cells have been subjected to pulsed electromagnetic field and wherein the vesicles are isolated from the parent cells using actin cytoskeletal disruptors, such as cytochalasin B. The CDVs are enriched for Transient Receptor Potential Channel 1 (TRPC1). The invention further relates to the uses of the CDVs as therapeutic agents in conditions associated with disruptive metabolism and inflammation; for instance, cancer.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE